ClinicalTrials.gg
CompletedNCT00992407Updated Mar 11, 2014Results posted

An Efficacy and Safety Study of Long Acting Injectable Risperidone and Oral Risperidone in Participants With Schizophrenia or Schizoaffective Disorder

A Phase 4 interventional study of Risperidone long acting injectables and Risperidone tablets in Schizophrenia, sponsored by Janssen Korea, Ltd., Korea. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2014-03-11.

Sponsored by Janssen Korea, Ltd., Korea (part of Johnson & Johnson) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 127 studies testing risperidone in Schizophrenia — 4 open to participants now, 4 under way, 2 of them phase 3. Risperidone · Schizophrenia.

Enrollment
82nd of 123
75 · median 100
Started
2007
with 6 others
Phase 4
63 of 127
2 open now
Registered
75th of 127
by date

Among the 127 studies testing risperidone in Schizophrenia, this one is the 82nd largest by enrollment of the 123 interventional ones that give a count, is one of 7 that started in 2007, is one of 63 in phase 4, and was the 75th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 127 studies testing risperidone in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About risperidone

Risperidone: first FDA approval 1993 (RISPERDAL), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies testing risperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of long acting injectable (LAI) risperidone and oral risperidone treatment on participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations, and withdrawal into the self) or schizoaffective disorder (a mixed psychiatric disorder relating to a complex psychotic state that has features of both schizophrenia and a mood disorder such as bipolar disorder).

Read the detailed description

This is a randomized (treatment group assigned by chance), open-label (all involved people know the identity of the study drug), active-controlled study to evaluate the improvement in social functioning among participants with schizophrenia taking LAI risperidone and oral risperidone tablet. The study drug will be administered for 52 weeks in flexible dose (range as per Investigator's discretion) and a total of 11 assessment visits will be conducted per participant, including Screening. The participant may be withdrawn from the trial for any medical reason at the sole discretion of the investigator. Before starting the study treatment, participants undergo the period of switching from the previous medication to risperidone for 4 weeks, and then they will be evaluated for tolerability for 2 weeks (run-in period for stabilizing to risperidone). In this 2-week period, participants will take oral risperidone. The efficacy will be primarily evaluated through Personal and Social Performance Scale. Safety will be evaluated through Abnormal Involuntary Movement Scale, Barnes Akathisia Rating Scale, and Simpson-Angus Rating Scale. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Risperidone
  • Risperdal
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: - Participants who will understand the objectives and necessary procedures of the study and have signed the form which specified that they were willing to participate in the study - Participants with schizophrenia or schizoaffective disorder requiring long-term antipsychotic drug therapy - Participants with pre-morbid global assessment of functioning score of 71 or higher at Screening - Participants who do not present abnormality in biochemistry and electrocardiography - Participants who will be compliant with the study requirements (that is, filling in the questionnaire by themselves) and who are capable of actually performing and willing to implementing them

Exclusion Criteria: - Participants who had taken clozapine for the past three months - Participants with mental retardation (Intelligence Quotient less than 70 at the screening) - Participants with history of or currently with a serious disease (cardiovascular, respiratory, neurological [including seizures or significant cerebrovascular], renal, hepatic, hematologic, endocrine, immunologic or other systemic disease) including clinically relevant abnormal level - Participants who have an allergic or hypersensitive reaction to risperidone or who are unresponsive to risperidone - Pregnant or lactating female participants

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Risperidone long acting injectables

    Drug: Risperidone long acting injectables

  • Active comparator
    Risperidone tablets

    Drug: Risperidone tablets

Interventions

  • Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.

    Also known as: Risperdal Consta

  • Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.

    Also known as: Risperdal

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52

    The PSP assesses degree of participant's dysfunction within 4 domains of behavior, socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1=absent to 6=very severe) in each of 4 domains. Based on the 4 domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

    Time frame: Baseline and Week 52

Secondary outcomes

  1. Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Score at Week 52

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Baseline and Week 52

  2. Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Week 52

    The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.

    Time frame: Baseline and Week 52

  3. Change From Baseline in Social Functioning Scale (SFS) Score at Week 52

    Social Functioning Scale (SFS) scores from 0 to 223 wherein, following categories were involved: Social Engagement (Score Range 0-15); Interpersonal Communication (Score Range 0-9); Recreational Activities (Score Range 0-45); Social Activities (Score Range 0-66; Independence Competence (Score Range 0-39); Independence Performance (Score Range 0-39); Occupational Activity (Score Range 0-10). Total score is sum of all sub scores and higher score indicates better level of social functioning.

    Time frame: Baseline and Week 52

  4. Change From Baseline in Emotional & Social Functioning Scale (SFS) Score at Week 52

    For emotional and SFS, mean scores of neuroticism-extroversion-openness (NEO) personality test, relationship style questionnaire (RSQ), state-trait anger expression inventory (STAXI), positive affect and negative affect schedule (PANAS), emotional intelligence (EI), beck depression inventory (BDI), and beck anxiety inventory (BAI) scales were calculated. Score ranges for each category as:60-300 for NEO, 30-150 for RSQ, 20-80 for STAXI, 20-100 for PANAS, 8-172 for EI, 0-63 for BDI and BAI. Higher score indicates improvement.

    Time frame: Baseline and Week 52

  5. Change From Baseline in Verbal Working Memory (VWM) Response Based on Neurocognitive Function Test (NCFT) at Week 52

    The NCFT is neuropsychological test which measures psychological functions. The VWM was measured by Korean-Wechsler Adults Intelligence Scale (K-WAIS), which consists of two subscales, the Verbal scale (6 subtests) and the Performance scale (5 subtests). The verbal tests were: information, comprehension, arithmetic, digit span, similarities, and vocabulary. Arithmetic and Digit Span test of Verbal WAIS scales was conducted. Arithmetic test (arithmetic questions were asked orally) involved calculations that measured concentration while manipulating mental mathematical problems. Digit span test (children were asked to repeat the orally given sequences of numbers either as heard or in reverse order) measured attention, concentration, and mental control. Here, mean number of correct responses in limited time period are reported for arithmetic (calculation) and Digit span. Increase in number of correct response indicates improvement.

    Time frame: Baseline and Week 52

  6. Change From Baseline in Trail Making Test Based on Neurocognitive Function Test (NCFT) at Week 52

    The NCFT is neuropsychological test which measures psychological functions. The Trail Making Test is composed of two Parts, A and B. Part A consists of 25 circles printed on a sheet of paper. Each circle contains a number from 1 to 25. The participant's task is to connect the circles with a pencil line as quickly as possible, beginning with the number 1 and proceeding in numerical sequence. Part B consists of 25 circles numbered from 1 to 13 and lettered from A to L. The task in Part B is to connect the circles, in sequence, alternating between numbers and letters. Here, mean number of seconds are represented required to complete each Part.

    Time frame: Baseline and Week 52

  7. Change From Baseline in Working Memory Based on Neurocognitive Function Test (NCFT) at Week 52

    The NCFT is neuropsychological test which measures psychological functions. Working memory was assessed using Controlled Oral Word Association Test (COWAT) which measured verbal fluency and is a sub-test of the multilingual aphasia examination. The COWAT uses the three letter set of C, F, and L to assess phonemic fluency. Individuals are given 1 minute to name as many words as possible beginning with one of the letters. The procedure is then repeated for the remaining two letters. More words indicate improvement.

    Time frame: Baseline and Week 52

  8. Change From Baseline in Continuous Performance Task (CPT) Based on Neurocognitive Function Test (NCFT) at Week 52

    The NCFT is neuropsychological test which measures psychological functions. The CPT assessed CPT (Omissions) and CPT (Commissions). Omission errors indicate the number of times the target was presented, but the participant did not respond/click the mouse. High omission rates indicate that the participant is either not paying attention (distractibility) to stimuli or has a sluggish response. Commission errors indicate the number of times the participant responded but no target was presented. A fast reaction time and high commission error rate points to difficulties with impulsivity. A slow reaction time with high commission and omission errors indicates inattention in general.

    Time frame: Baseline and Week 52

  9. Change From Baseline in Theory of Mind (TOM) Scale Score at Week 52

    The TOM scale is used to assess the ability of participant to infer other's mental states. It includes recognition that other individuals experience thoughts, feelings, intentions, and desires. It is measured by cartoon task, score ranging from 0-30 and stork task which includes stork task set A (false belief), stork task set B (double bluff, white lie, persuasion, misunderstanding), and physical story, score ranging from 0-12, 0-26 and 0-24 respectively. Higher score indicates improvement.

    Time frame: Baseline and Week 52

  10. Change From Baseline in Psychosocial Well-being Index (PWI) Score at Week 52

    Psychosocial Well-being Index (PWI) is a questionnaire about how the participant feels and how the things had been going with them. Total score ranges from 0 to 135, where lower score indicates worsening.

    Time frame: Baseline and Week 52

  11. Change From Baseline in Global Assessment of Functioning (GAF) Test Score at Week 52

    The GAF is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.

    Time frame: Baseline and Week 52

  12. Change From Baseline in Scale to Assess Unawareness of Mental Disorder (SUMD) Score at Week 52

    The SUMD scale is a semi-structured scale that assesses participant's awareness of and insight into their illness, that is, the present level of insight. SUMD total score ranges from 0-27, with higher scores indicating poorer insight. The scale consists of nine items score ranging from 1 to 3, with higher scores indicating poorer insight. Score for each item is summed to produce the total score.

    Time frame: Baseline and Week 52

  13. Change From Baseline in Drug Attitude Inventory-10 (DAI-10) Score at Week 52

    The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. Score ranges from (-) 10 to 10. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant).

    Time frame: Baseline and Week 52

  14. Change From Baseline in Members for Outpatients, Members Visiting Inpatients, Affected Members and Visiting Inpatients at Week 52

    Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 4 questions are related to number of members for outpatients, number of members visiting inpatients, number of affected members and number of visiting inpatients. Mean-calculations were done for all questions. Higher value indicates more disease burden. Change from Baseline is the value at Week 52 minus value at Baseline.

    Time frame: Baseline and Week 52

  15. Change From Baseline in Days of Hospitalization, Number of Days Affected by Participants and Family, at Week 52

    Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 3 questions are related to days of hospitalization, number of days affected by participants and family per participant within reporting interval score. Mean-calculations were done for all questions. Change from Baseline is the value at Week 52 minus value at Baseline.

    Time frame: Baseline and Week 52

  16. Change From Baseline in Total Outpatients and Inpatients Hours at Week 52

    Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 2 questions are related to total outpatients and inpatients hours. Total outpatients hours and total inpatient hours indicate the total hours spent by outpatients and inpatients respectively at Investigator site.Mean-calculations were done for all questions. Higher value indicates more disease burden. Change from Baseline is the value at Week 52 minus value at Baseline.

    Time frame: Baseline and Week 52

  17. Change From Baseline in Travelling Fee for Outpatients, Hospitalization Travelling Fee and Salary Paid a Participant Before Being Ill at Week 52

    Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 3 questions are related to travelling fee for outpatients, hospitalization travelling fee and salary paid a participant before being ill. Mean-calculations were done for all questions. Travelling fee, hospitalization travelling fee and salary paid were assessed for every past three months. Higher value indicates more disease burden. Change from Baseline is the value at Week 52 minus value at Baseline.

    Time frame: Baseline and Week 52

  18. Change From Baseline in Number of Outpatient Clinic Visits at Week 52

    Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 1 question is related to number of outpatient clinic visits. Mean-calculations were done for all questions. Higher value indicates more disease burden. Change from Baseline is the value at Week 52 minus value at Baseline.

    Time frame: Baseline and Week 52

  19. Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score at Week 52

    The AIMS rates the severity of involuntary movements from 0 (none) to 4 (severe), including facial and oral movements, extremity movements, trunk movements, global and judgments, and 2 additional items concerning dental status (yes/no). A total score (ranging from 0 to 28) will be calculated as the sum of items 1 to 7.

    Time frame: Baseline and Week 52

  20. Change From Baseline in Simpson and Angus Rating Scale (SAS) Score at Week 52

    The SAS rates 10 items from 0 (normal) to 4 (extreme), including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, Glabellar tap, tremor and salivation. The SAS global score is the average score (total sum of items score divided by the number of items) and ranges between 0 and 4, where the higher score denotes more severe condition of extra pyramidal symptoms.

    Time frame: Baseline and Week 52

  21. Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 52

    The BARS includes an objective rating, 2 subjective ratings of symptoms of akathisia (awareness of restlessness and reported distress related to restlessness: ranging from 0 to 3), and a global clinical rating of akathisia (GCRA), ranging from 0 (absent) to 5 (severe). The global rating score, that is scored separately, is the most relevant measure of severity of akathisia. Higher scores denote worsening akathisia.

    Time frame: Baseline and Week 52

07

Results

Posted Mar 11, 2014

Participant flow

Participant flow — Overall Study
MilestoneRisperidone InjectionRisperidone Tablets
Started3738
Treated2025
Completed614
Not completed3124
Withdrew: Protocol violation21
Withdrew: Lost to follow-up33
Withdrew: Adverse event32
Withdrew: Protocol violation & adverse events24
Withdrew: Other20
Withdrew: Loss of follow-up & adverse events21
Withdrew: Study medication not administered1713

Outcome measures

PrimaryChange From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52

The PSP assesses degree of participant's dysfunction within 4 domains of behavior, socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate degree of difficulty (1=absent to 6=very severe) in each of 4 domains. Based on the 4 domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Personal and Social Performance (PSP) Scale Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Baseline50.65 ± 14.1958.71 ± 9.82
Change at Week 525.35 ± 9.955.96 ± 11.22
Statistical analysis
  • Risperidone Long Acting Injectables vs Risperidone Tablets · t-test, 2 sided · p = 0.8595 · Mean difference (final values): -0.61 · 95% CI -7.5 to 6.3
SecondaryChange From Baseline in Positive and Negative Syndrome Scale (PANSS) Score at Week 52

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Baseline78.0 ± 11.469.5 ± 11.9
Change at Week 52-11.7 ± 18.8-13.0 ± 15.7
Statistical analysis
  • Risperidone Long Acting Injectables vs Risperidone Tablets · t-test, 2 sided · p = 0.8118 · Mean difference (final values): 1.29 · 95% CI -9.6 to 12.2
SecondaryChange From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Week 52

The CGI rating scale is a 7-point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Global Impression-Severity Scale (CGI-S) Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablet
Baseline3.4 ± 1.32.8 ± 1.1
Change at Week 52-0.6 ± 0.9-0.7 ± 1.1
SecondaryChange From Baseline in Social Functioning Scale (SFS) Score at Week 52

Social Functioning Scale (SFS) scores from 0 to 223 wherein, following categories were involved: Social Engagement (Score Range 0-15); Interpersonal Communication (Score Range 0-9); Recreational Activities (Score Range 0-45); Social Activities (Score Range 0-66; Independence Competence (Score Range 0-39); Independence Performance (Score Range 0-39); Occupational Activity (Score Range 0-10). Total score is sum of all sub scores and higher score indicates better level of social functioning.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Social Functioning Scale (SFS) Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Baseline (n=16, 23)99.6 ± 27.0103.5 ± 33.2
Change at Week 52 (n=4,14)2.3 ± 5.99.6 ± 30.2
SecondaryChange From Baseline in Emotional & Social Functioning Scale (SFS) Score at Week 52

For emotional and SFS, mean scores of neuroticism-extroversion-openness (NEO) personality test, relationship style questionnaire (RSQ), state-trait anger expression inventory (STAXI), positive affect and negative affect schedule (PANAS), emotional intelligence (EI), beck depression inventory (BDI), and beck anxiety inventory (BAI) scales were calculated. Score ranges for each category as:60-300 for NEO, 30-150 for RSQ, 20-80 for STAXI, 20-100 for PANAS, 8-172 for EI, 0-63 for BDI and BAI. Higher score indicates improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Emotional & Social Functioning Scale (SFS) Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
NEO personality test: Baseline (n=16,21)178.7 ± 21.8173.7 ± 22.9
EI: Baseline (n=16,21)151.4 ± 23.1152.9 ± 26.4
RSQ: Baseline (n=16,21)84.1 ± 18.987.1 ± 14.8
STAXI: Baseline (n=16,21)37.4 ± 11.731.7 ± 10.8
PANAS: Baseline (n=16,21)55.1 ± 14.451.0 ± 10.6
BDI: Baseline (n=16,21)14.8 ± 11.316.9 ± 15.0
BAI: Baseline (n=16,21)17.9 ± 16.915.3 ± 13.9
NEO personality test:Change at Week 52 (n=9,17)-1.1 ± 23.82.2 ± 21.0
RSQ: Change at Week 52 (n=9,17)-4.1 ± 16.7-8.5 ± 26.3
STAXI:Change at Week 52 (n=9,17)0.3 ± 11.6-0.2 ± 15.6
PANAS: Change at Week 52 (n=9,17)-2.8 ± 14.2-2.8 ± 17.3
EI: Change at Week 52 (n=9,17)2.2 ± 25.52.4 ± 19.5
BDI:Change at Week 52 (n=9,17)1.7 ± 9.6-6.3 ± 11.1
BAI: Change at Week 52 (n=9,17)0.9 ± 12.2-3.9 ± 12.1
SecondaryChange From Baseline in Verbal Working Memory (VWM) Response Based on Neurocognitive Function Test (NCFT) at Week 52

The NCFT is neuropsychological test which measures psychological functions. The VWM was measured by Korean-Wechsler Adults Intelligence Scale (K-WAIS), which consists of two subscales, the Verbal scale (6 subtests) and the Performance scale (5 subtests). The verbal tests were: information, comprehension, arithmetic, digit span, similarities, and vocabulary. Arithmetic and Digit Span test of Verbal WAIS scales was conducted. Arithmetic test (arithmetic questions were asked orally) involved calculations that measured concentration while manipulating mental mathematical problems. Digit span test (children were asked to repeat the orally given sequences of numbers either as heard or in reverse order) measured attention, concentration, and mental control. Here, mean number of correct responses in limited time period are reported for arithmetic (calculation) and Digit span. Increase in number of correct response indicates improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · Correct responses
Change From Baseline in Verbal Working Memory (VWM) Response Based on Neurocognitive Function Test (NCFT) at Week 52
Correct responsesRisperidone Long Acting InjectablesRisperidone Tablets
VWM (Calculation):Baseline (n=11,14)7.5 ± 2.29.3 ± 4.1
VWM (Numbers):Baseline (n=11,14)11.6 ± 5.111.8 ± 4.6
VWM (Calculation):Change at Week 52 (n=7,12)2.0 ± 2.81.0 ± 4.1
VWM (Numbers):Change at Week 52 (n=7,12)1.3 ± 3.62.3 ± 3.1
SecondaryChange From Baseline in Trail Making Test Based on Neurocognitive Function Test (NCFT) at Week 52

The NCFT is neuropsychological test which measures psychological functions. The Trail Making Test is composed of two Parts, A and B. Part A consists of 25 circles printed on a sheet of paper. Each circle contains a number from 1 to 25. The participant's task is to connect the circles with a pencil line as quickly as possible, beginning with the number 1 and proceeding in numerical sequence. Part B consists of 25 circles numbered from 1 to 13 and lettered from A to L. The task in Part B is to connect the circles, in sequence, alternating between numbers and letters. Here, mean number of seconds are represented required to complete each Part.

Time frame:
Baseline and Week 52
Reported as:
Mean · Seconds
Change From Baseline in Trail Making Test Based on Neurocognitive Function Test (NCFT) at Week 52
SecondsRisperidone Long Acting InjectablesRisperidone Tablets
Trail A Making Test:Baseline (n=11,15)52.6 ± 26.650.7 ± 28.9
Trail B Making Test:Baseline (n=11,15)146.0 ± 74.2147.3 ± 118.2
Trail A Making Test:Change at Week 52 (n=7,12)5.9 ± 14.9-7.8 ± 10.3
Trail B Making Test:Change at Week 52 (n=7,12)-32.3 ± 59.3-19.5 ± 37.9
SecondaryChange From Baseline in Working Memory Based on Neurocognitive Function Test (NCFT) at Week 52

The NCFT is neuropsychological test which measures psychological functions. Working memory was assessed using Controlled Oral Word Association Test (COWAT) which measured verbal fluency and is a sub-test of the multilingual aphasia examination. The COWAT uses the three letter set of C, F, and L to assess phonemic fluency. Individuals are given 1 minute to name as many words as possible beginning with one of the letters. The procedure is then repeated for the remaining two letters. More words indicate improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · Words
Change From Baseline in Working Memory Based on Neurocognitive Function Test (NCFT) at Week 52
WordsRisperidone Long Acting InjectablesRisperidone Tablets
WM (Digital Span):Baseline (n=10,12)11.6 ± 4.714.3 ± 5.1
WM (Coris Block): Baseline (n=8,13)10.5 ± 5.314.9 ± 5.2
WM (Digital Span):Change at Week 52 (n=6,10)1.0 ± 3.40.5 ± 3.0
WM (Coris Block): Change at Week 52 (n=5,9)4.6 ± 9.6-0.7 ± 4.7
SecondaryChange From Baseline in Continuous Performance Task (CPT) Based on Neurocognitive Function Test (NCFT) at Week 52

The NCFT is neuropsychological test which measures psychological functions. The CPT assessed CPT (Omissions) and CPT (Commissions). Omission errors indicate the number of times the target was presented, but the participant did not respond/click the mouse. High omission rates indicate that the participant is either not paying attention (distractibility) to stimuli or has a sluggish response. Commission errors indicate the number of times the participant responded but no target was presented. A fast reaction time and high commission error rate points to difficulties with impulsivity. A slow reaction time with high commission and omission errors indicates inattention in general.

Time frame:
Baseline and Week 52
Reported as:
Mean · Errors
Change From Baseline in Continuous Performance Task (CPT) Based on Neurocognitive Function Test (NCFT) at Week 52
ErrorsRisperidone Long Acting InjectablesRisperidone Tablets
CPT (Omissions):Baseline (n=11,15)11.0 ± 13.514.2 ± 34.3
CPT (Comissions):Baseline (n=11,15)17.4 ± 37.129.3 ± 54.5
CPT (Omissions):Change at Week 52 (n=7,12)1.6 ± 17.5-12.2 ± 38.4
CPT (Comissions):Change at Week 52 (n=7,12)-3.9 ± 4.1-0.6 ± 2.3
SecondaryChange From Baseline in Theory of Mind (TOM) Scale Score at Week 52

The TOM scale is used to assess the ability of participant to infer other's mental states. It includes recognition that other individuals experience thoughts, feelings, intentions, and desires. It is measured by cartoon task, score ranging from 0-30 and stork task which includes stork task set A (false belief), stork task set B (double bluff, white lie, persuasion, misunderstanding), and physical story, score ranging from 0-12, 0-26 and 0-24 respectively. Higher score indicates improvement.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Theory of Mind (TOM) Scale Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Cartoon task:Baseline (n=11,13)13.8 ± 8.718.5 ± 9.3
Stork Task Set A: Baseline (n=9,12)6.0 ± 2.06.6 ± 2.8
Stork Task Set B: Baseline (n=11,14)14.2 ± 6.215.5 ± 6.8
Cartoon task:Change at Week 52(n=7,11)5.0 ± 7.92.7 ± 3.9
Stork Task Set A:Change at Week 52(n=7,11)1.0 ± 3.60.8 ± 4.8
Stork Task Set B:Change at Week 52(n=4,8)1.0 ± 8.31.5 ± 3.6
Physical story: Baseline (n=11,14)12.0 ± 5.013.6 ± 4.4
Physical story:Change at Week 52(n=7,11)1.4 ± 5.22.1 ± 3.9
SecondaryChange From Baseline in Psychosocial Well-being Index (PWI) Score at Week 52

Psychosocial Well-being Index (PWI) is a questionnaire about how the participant feels and how the things had been going with them. Total score ranges from 0 to 135, where lower score indicates worsening.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Psychosocial Well-being Index (PWI) Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Baseline (n=16,22)93.8 ± 21.996.0 ± 14.2
Change at Week 52 (n=9,18)10.7 ± 22.10.7 ± 15.1
Statistical analysis
  • Risperidone Long Acting Injectables vs Risperidone Tablets · Student's t-test · p = 0.1768 · Mean difference (final values): 10.00 · 95% CI -4.8 to 24.8
SecondaryChange From Baseline in Global Assessment of Functioning (GAF) Test Score at Week 52

The GAF is a 100-point tool rating overall psychological, social and occupational functioning of adults. The higher score range (91 to 100) refers to a superior functioning in a wide range of activities, and absence of symptoms. The lower score range (1 to 10) refers to persistent danger of severely hurting self or others; or persistent inability to maintain minimum personal hygiene; or serious suicidal act with clear expectation of death.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Global Assessment of Functioning (GAF) Test Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Baseline (n=17,24)58.3 ± 16.763.4 ± 10.5
Change at Week 52 (n=8,17)5.4 ± 11.25.7 ± 15.2
Statistical analysis
  • Risperidone Long Acting Injectables vs Risperidone Tablets · Student's t-test · p = 0.9569 · Mean difference (final values): -0.33 · 95% CI -12.8 to 12.2
SecondaryChange From Baseline in Scale to Assess Unawareness of Mental Disorder (SUMD) Score at Week 52

The SUMD scale is a semi-structured scale that assesses participant's awareness of and insight into their illness, that is, the present level of insight. SUMD total score ranges from 0-27, with higher scores indicating poorer insight. The scale consists of nine items score ranging from 1 to 3, with higher scores indicating poorer insight. Score for each item is summed to produce the total score.

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Scale to Assess Unawareness of Mental Disorder (SUMD) Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Baseline (n=17,24)12.1 ± 5.110.6 ± 5.0
Change at Week 52 (n=6,17)-4.8 ± 6.2-3.5 ± 3.5
Statistical analysis
  • Risperidone Long Acting Injectables vs Risperidone Tablets · t-test, 2 sided · p = 0.5294 · Mean difference (final values): 0.58 · 95% CI -5.5 to 2.9
SecondaryChange From Baseline in Drug Attitude Inventory-10 (DAI-10) Score at Week 52

The DAI-10 is a 10-item questionnaire to assess 1) subjective experience of drug and 2) attitudes and beliefs toward neuroleptics which may influence compliance in schizophrenia participants. Score ranges from (-) 10 to 10. It is the binary scale assessing the participant's subjective response. A 'compliant' response is scored as +1; a dysphoric response is scored as -1. A positive sum of items indicates a positive subjective response (SR); a negative sum of scores indicates a negative SR (non-compliant).

Time frame:
Baseline and Week 52
Reported as:
Mean · units on a scale
Change From Baseline in Drug Attitude Inventory-10 (DAI-10) Score at Week 52
units on a scaleRisperidone InjectionRisperidone Tablet
Baseline (n=15,18)4.1 ± 4.65.0 ± 4.1
Change at Week 52 (n=7,15)-4.7 ± 7.8-1.1 ± 5.9
SecondaryChange From Baseline in Members for Outpatients, Members Visiting Inpatients, Affected Members and Visiting Inpatients at Week 52

Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 4 questions are related to number of members for outpatients, number of members visiting inpatients, number of affected members and number of visiting inpatients. Mean-calculations were done for all questions. Higher value indicates more disease burden. Change from Baseline is the value at Week 52 minus value at Baseline.

Time frame:
Baseline and Week 52
Reported as:
Mean · participants
Change From Baseline in Members for Outpatients, Members Visiting Inpatients, Affected Members and Visiting Inpatients at Week 52
participantsRisperidone Long Acting InjectablesRisperidone Tablets
Members for outpatients:Baseline(n=13,16)0.8 ± 0.40.7 ± 0.7
Members visiting inpatients (MVI):Baseline(n=6,9)2.2 ± 2.12.9 ± 2.6
Affected members:Baseline(n=11,14)0.6 ± 0.70.7 ± 1.0
Visiting inpatients:Baseline(n=7,8)6.0 ± 6.66.1 ± 4.6
Members for outpatients:Change at Week 52(n=8,13)-0.3 ± 0.5-0.3 ± 0.6
MVI:Change at Week52(n=0,3)0 ± 0-2.7 ± 3.1
Affected members:Change at Week52(n=4,10)-0.3 ± 0.5-0.4 ± 0.7
Visiting inpatients:Change at Week52(n=0,3)0 ± 0-5.0 ± 5.0
SecondaryChange From Baseline in Days of Hospitalization, Number of Days Affected by Participants and Family, at Week 52

Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 3 questions are related to days of hospitalization, number of days affected by participants and family per participant within reporting interval score. Mean-calculations were done for all questions. Change from Baseline is the value at Week 52 minus value at Baseline.

Time frame:
Baseline and Week 52
Reported as:
Mean · days
Change From Baseline in Days of Hospitalization, Number of Days Affected by Participants and Family, at Week 52
daysRisperidone Long Acting InjectablesRisperidone Tablets
Hospitalization days:Baseline(n=11,18)19.4 ± 21.39.8 ± 13.4
Days affected:Baseline(n=8,11)34.0 ± 46.424.3 ± 34.5
Family affected days:Baseline(n=9,12)2.9 ± 4.82.0 ± 3.4
Hospitalization days:Change at Week 52(n=3,12)-14.0 ± 24.2-10.0 ± 15.0
Days affected:Change at Week 52(n=3,10)-30.0 ± 52.0-25.3 ± 33.1
Family affected days:Change at Week 52(n=4,10)-0.3 ± 2.1-1.5 ± 3.2
SecondaryChange From Baseline in Total Outpatients and Inpatients Hours at Week 52

Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 2 questions are related to total outpatients and inpatients hours. Total outpatients hours and total inpatient hours indicate the total hours spent by outpatients and inpatients respectively at Investigator site.Mean-calculations were done for all questions. Higher value indicates more disease burden. Change from Baseline is the value at Week 52 minus value at Baseline.

Time frame:
Baseline and Week 52
Reported as:
Mean · hours
Change From Baseline in Total Outpatients and Inpatients Hours at Week 52
hoursRisperidone Long Acting InjectablesRisperidone Tablets
Total outpatients hours:Baseline(n=9,13)1.7 ± 1.01.6 ± 0.7
Total inpatient hours:Baseline(n=5,8)1.4 ± 1.51.4 ± 0.9
Total outpatients hours:Change at Week 52(n=4,9)0.1 ± 1.0-0.2 ± 0.4
Total inpatient hours:Change at Week 52(n=0,3)0.0 ± 0.0-1.0 ± 1.0
SecondaryChange From Baseline in Travelling Fee for Outpatients, Hospitalization Travelling Fee and Salary Paid a Participant Before Being Ill at Week 52

Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 3 questions are related to travelling fee for outpatients, hospitalization travelling fee and salary paid a participant before being ill. Mean-calculations were done for all questions. Travelling fee, hospitalization travelling fee and salary paid were assessed for every past three months. Higher value indicates more disease burden. Change from Baseline is the value at Week 52 minus value at Baseline.

Time frame:
Baseline and Week 52
Reported as:
Mean · Won
Change From Baseline in Travelling Fee for Outpatients, Hospitalization Travelling Fee and Salary Paid a Participant Before Being Ill at Week 52
WonRisperidone Long Acting InjectablesRisperidone Tablets
Travel fee for outpatient(TFO):Baseline(n=12,14)4645.8 ± 4739.64850.0 ± 6401.1
Hospitalization fee:Baseline(n=4,6)3500.0 ± 4725.89500.0 ± 8043.6
Salary paid:Baseline(n=4,6)0.0 ± 0.03000.0 ± 7348.5
TFO:Change at Week 52(n=12,14)-658.3 ± 2168.0183.3 ± 10837.4
Hospitalization fee:Change at Week 52(n=0,3)0 ± 0.0-7333.3 ± 9451.6
Salary paid:Change at Week 52(n=3,6)0 ± 0.0-3000.0 ± 7348.5
SecondaryChange From Baseline in Number of Outpatient Clinic Visits at Week 52

Healthcare economics questionnaire consists of 13-Questions, which measured disease burden on participant; out of which 1 question is related to number of outpatient clinic visits. Mean-calculations were done for all questions. Higher value indicates more disease burden. Change from Baseline is the value at Week 52 minus value at Baseline.

Time frame:
Baseline and Week 52
Reported as:
Mean · number of visits
Change From Baseline in Number of Outpatient Clinic Visits at Week 52
number of visitsRisperidone Long Acting InjectablesRisperidone Tablets
Outpatient clinic visits:Baseline(n=13,20)4.7 ± 4.24.4 ± 2.5
Outpatient clinic visits:Change at Week 52(n=7,14)2.4 ± 6.31.1 ± 3.1
SecondaryChange From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score at Week 52

The AIMS rates the severity of involuntary movements from 0 (none) to 4 (severe), including facial and oral movements, extremity movements, trunk movements, global and judgments, and 2 additional items concerning dental status (yes/no). A total score (ranging from 0 to 28) will be calculated as the sum of items 1 to 7.

Time frame:
Baseline and Week 52
Reported as:
Median · units on a scale
Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Baseline (n=20,25)0 ± 4.60 ± 4.1
Change at Week 52 (n=19,20)0 ± 5.60 ± 4.8
SecondaryChange From Baseline in Simpson and Angus Rating Scale (SAS) Score at Week 52

The SAS rates 10 items from 0 (normal) to 4 (extreme), including gait, arm dropping, shoulder shaking, elbow rigidity, wrist rigidity, leg pendulousness, head rotation, Glabellar tap, tremor and salivation. The SAS global score is the average score (total sum of items score divided by the number of items) and ranges between 0 and 4, where the higher score denotes more severe condition of extra pyramidal symptoms.

Time frame:
Baseline and Week 52
Reported as:
Median · units on a scale
Change From Baseline in Simpson and Angus Rating Scale (SAS) Score at Week 52
units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Baseline (n=20,25)0 ± 4.60 ± 4.1
Change at Week 52 (n=19,22)0 ± 5.60 ± 4.8
SecondaryChange From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 52

The BARS includes an objective rating, 2 subjective ratings of symptoms of akathisia (awareness of restlessness and reported distress related to restlessness: ranging from 0 to 3), and a global clinical rating of akathisia (GCRA), ranging from 0 (absent) to 5 (severe). The global rating score, that is scored separately, is the most relevant measure of severity of akathisia. Higher scores denote worsening akathisia.

Time frame:
Baseline and Week 52
Reported as:
Mean · Units on a scale
Change From Baseline in Barnes Akathisia Rating Scale (BARS) Score at Week 52
Units on a scaleRisperidone Long Acting InjectablesRisperidone Tablets
Restlessness total score: Baseline(n=20,25)0.80 ± 1.110.40 ± 0.71
GCRA: Baseline(n=20,25)0.40 ± 0.600.32 ± 0.48
Restlessness total score:Change at Week52(n=19,22)-0.16 ± 1.120.00 ± 0.87
GCRA: Change at Week 52(n=19,22)0.05 ± 0.71-0.09 ± 0.68

Adverse events

Collected over Baseline up to Week 52. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Risperidone Injection—0/20 (0%)11/20 (55%)
Risperidone Tablets—0/25 (0%)13/25 (52%)
Most frequent other events
Showing 10 of 25
Most frequent other events
EventRisperidone InjectionRisperidone Tablets
AkathisisaNervous system disorders2/204/25
AnxietyPsychiatric disorders2/200/25
Weight increasedInvestigations2/201/25
Muscle rigidityMusculoskeletal and connective tissue disorders2/200/25
dystoniaNervous system disorders1/202/25
Upper respiratory tract infectionInfections and infestations0/202/25
dysarthriaNervous system disorders1/201/25
ParaesthesiaNervous system disorders1/200/25
InsomniaPsychiatric disorders1/200/25
Obsessive thoughtsPsychiatric disorders1/200/25

Baseline characteristics

"N" (number of participants analyzed) signifies the participants evaluable for this measure.

Age, Continuous
Age, Continuous(years)Risperidone InjectionRisperidone TabletsTotal
Mean36.9 ± 10.532.8 ± 9.434.5 ± 10.0
Sex: Female, Male
Sex: Female, Male(Participants)Risperidone InjectionRisperidone TabletsTotal
Female8816
Male91625
08

Study locations

1 site
  • Ansan, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Dec 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2009
First posted
Oct 9, 2009
Start
Dec 2007
Primary completionActual
Dec 2010
CompletionActual
Dec 2010
Results first posted
Mar 11, 2014
Last update
Mar 11, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 11, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00992407
Responsible party
Sponsor
First posted
Oct 9, 2009
Start date
Dec 2007
Primary completion
Dec 2010
Completion
Dec 2010
Results posted
Mar 11, 2014
Last update
Mar 11, 2014

Study contacts

Janssen Korea, Ltd. Clinical Trial
study director · Janssen Korea, Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risperidone

Start the discussion